You are here: Home » Archives for 2021

Why SNOMED CT? New platform presents a refreshed case for investing in the comprehensive clinical terminology

London, United Kingdom, Dec. 16, 2021 (GLOBE NEWSWIRE) — SNOMED International released today its refreshed SNOMED CT Case for Investment report. Available on a new interactive platform, the Case for Investment presents evidence that SNOMED CT adds measurable value to a broad range of primary and secondary health processes leveraging SNOMED CT encoded data to enable improved patient outcomes. Through the narrative, the report provides accessible and understandable answers to questions such as, "what is SNOMED CT?", "what makes SNOMED CT unique?', "how and where is it in use globally?" and "why invest in SNOMED CT?"

SNOMED CT, the most comprehensive and multilingual clinical healthcare terminology in the world, possesses unique characteristics that differentiate it from other classifications and terminologies. Among these characteristics are SNOMED CT's position as a core reference terminology, its clinically comprehensive 350,000+ concepts supported by a machine–readable semantic network, broad use and mandate in select countries.

Showcasing real world use and outcomes of SNOMED CT is the best way to demonstrate its value, understanding that SNOMED CT must be embedded in a clinical information system, health data & analytics platform or an interoperability solution for it to function. Through the Case for Investment, 10 examples of SNOMED CT use across data entry and integration, clinical information sharing, point of care analytics, population and management analytics and research domains have been featured. Ranging across different countries such as Australia, Canada, China, United Kingdom, United States, continued collection of additional SNOMED CT case studies remains an ongoing priority.

SNOMED International CEO, Don Sweete, commented on the development and outcomes of the Case for Investment. "There has been a tremendous evolution in SNOMED CT over the past 10 years and this report demonstrates the value that it offers healthcare systems and stakeholders worldwide" said Sweete. "With a complement of 41 Members that represent health systems globally, continuously refreshed knowledge and analysis on the nature, utility and value of standards like SNOMED CT can't be overstated. Health system decision–makers need to be equipped with clear knowledge of how their investments in SNOMED CT translate into positive outcomes for the health of their nation's citizens."

In terms of conclusions, the report presents SNOMED CT as a scalable and "fit for purpose" clinical terminology, adhering to international criteria, data quality and suitability requirements. A part of the bigger picture, SNOMED CT is one of many contributing factors to improving patient outcomes, and studies show that the use of SNOMED CT–embedded systems can provide significant qualitative and quantitative patient outcome benefits.

Looking forward, SNOMED CT must also contemplate how it enables the future needs of medicine and research. A healthcare industry that is ever evolving, the future opportunities for SNOMED CT will be driven by new healthcare data sources and new healthcare technologies such as national cohorts, big data and AI, clinical genomics, phenomics and environment, etc.

Experience the breadth of the SNOMED CT Case for Investment through the organization's interactive value platform at value.snomed.org.

Attachment


GLOBENEWSWIRE (Distribution ID 8412878)

Cinturion Participates at Expo 2020 Dubai UAE

HAMILTON, Bermuda, Dec. 16, 2021 (GLOBE NEWSWIRE) — Cinturion Corp Ltd. a global provider of scalable, subsea and terrestrial capacity–based network solutions spanning India, the Middle East and Europe, is excited to announce their participation at Expo 2020 Dubai, the largest event ever staged in the Middle East. Expo 2020 brings together over 200 participants from around the world with the common goal of supporting advancements in education, technology, and innovations that will shape the future and unlock new opportunities.

On January 13, 2022, Cinturion along with their partner GCCIA (Gulf Cooperation Council Interconnection Authority) will participate in a panel discussion session on the topics of global communications networks, the latest communications technologies, and the investment opportunities offered by GCCIA.

GCCIA along with other Telcom specialists will address:

  • The evaluation of connectivity in MENA region over the past years.
  • The potential of terrestrial cable in GCC and the opportunities it brings for the Hyperscale's / Cloud companies as well as large enterprises.
  • The challenges in communication technologies for long terrestrial cable and how to overcome the challenge.

Cinturion will have the opportunity to reveal their TEAS "" Trans Europe Asia System. The most advanced new–build network that will fulfill demand for an open–access system with the lowest latency and most diverse routes between India, the Middle East & Europe. TEAS will provide much needed capacity, speed, and redundancy to companies in the region, particularly new data centers as well as content and cloud service providers.

TEAS network consists of two diverse connections across the Mediterranean Sea, continuing with two diverse paths inter–linking the Middle East, with multiple routes across the Arabian Peninsula, and a route through the Gulf of Aqaba and the Red Sea. This first new dual path (subsea and terrestrial) system of its kind will provide geographic routes between Pescara, Italy and Marseille, France and Mumbai, India. TEAS will enable new services with its unique and robust optical capabilities to support modern Data Center deployments, bringing broadband and ultra–low latency access to European, Middle East and Indian markets. When complete, TEAS will offer individual fiber ownership and open a new passage for internet traffic to a broad range of customers.

For information on GCCIA contact Alaa Rahma, Email: arahma@gccia.com.sa
Go to https://www.gccia.com.sa for further information.

For Cinturion and TEAS sales contact Bill Marra, bmarra@cinturiongroup.com. Media contact Lisa Cruise, lcruise@cinturiongroup.com.


GLOBENEWSWIRE (Distribution ID 8413122)

Intelligent Systems Announces Name Change to CoreCard

NORCROSS, Ga., Dec. 15, 2021 (GLOBE NEWSWIRE) — Intelligent Systems Corporation (NYSE: INS), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today that it is changing its name to CoreCard Corporation.

The Company anticipates its common stock will begin trading using new ticker symbol "CCRD" at the commencement of trading on December 29, 2021, and that its common stock will continue to trade on the NYSE under the symbol "INS" until the closing of trading on December 28, 2021.

The Company's corporate structure will not be changing, nor will its financial reporting.

Leland Strange, CEO and Chairman, stated, "This change highlights our goal to grow our industry leading revolving credit platform as the primary business of the company. Intelligent Systems Corporation was one of the early public technology companies with its IPO in 1980 and over the years it has founded, invested, and grown many technology brands including Peachtree Software and Quadram Corporation. CoreCard was one of our investments and trading under our new name reflects the singular long–term focus to growing CoreCard and delivering value to shareholders."

About CoreCard Corporation

CoreCard Corporation is a pioneering card management platform built for the future of global transactions in a digital world. Dedicated to continual technological innovation in the ever–evolving payments industry backed by decades of deep expertise in credit card offerings, CoreCard helps customers conceptualize, implement, and manage all aspects of their issuing card programs. Keenly focused on steady, sustainable growth, CoreCard has earned the trust of some of the largest companies and financial institutions in the world, providing truly real–time transactions via their proven, reliable platform operating on private on–premise and leading cloud technology infrastructure.

Further information is available on the company's website at www.corecard.com or by calling the company at 770–381–2900.

Forward–Looking Statements

The forward–looking statements in this press release are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those indicated by the forward–looking statements because of various risks and uncertainties including those listed in Item 1A of the Company's Annual Report on Form 10–K and in the Company's other filings and reports with the Securities and Exchange Commission. All of the risks and uncertainties are beyond the ability of the Company to control, and in many cases, the Company cannot predict the risks and uncertainties that could cause its actual results to differ materially from those indicated by the forward–looking statements. When used in this press release, the words "believes," "plans," "expects," "will," "intends," "continue," "outlook," "progressing," and "anticipates" and similar expressions as they relate to the Company or its management are intended to identify forward–looking statements. Except as required by law, the Company is not obligated to publicly release any revisions to these forward–looking statements to reflect the events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.


GLOBENEWSWIRE (Distribution ID 8411827)

Blue California Expands Natural Flavor and Fragrance Portfolio with Production of Clean, Natural, and Sustainable Nerolidol

Rancho Santa Margarita, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) — Blue California announced the expansion of its natural flavor and fragrance portfolio of captive ingredients by producing a clean, sustainable nerolidol.

Nerolidol is a rare sesquiterpene alcohol ubiquitous in nature and found in many flowers and plants, particularly in Seville orange flower, also known as Neroli, which gives the aroma chemical its name.

It is recognized for its floral, woody aroma and can also be described as a fresh scent, blending well with citrus, apple, or rose but light enough to complement any type of scent or flavor. Nerolidol is therefore ideal for use in many applications and known for its relaxing effects.

Many brands looking to make products at a large scale using nerolidol find it to be cost–prohibitive and, for that reason, it hasn't been widely used in modern–day product applications.

Yet, consumers seek clean–label fragrance products that are easy on the planet and fit into the clean and conscious fragrance and beauty movement. The Innova Beauty & Personal Care Survey 2020 notes that 51% of global consumers indicate that natural ingredients are very or extremely important to them when purchasing fragrances.

“Biotechnology is opening doors to sustainable ingredients that weren't previously possible,” said Kathy Oglesby, head of flavors and fragrances at Blue California. “Our collaboration with innovation partner Conagen provides efficient and effective commercialization, leading us to deliver to our client–creators a full range of captive ingredients, trademarked Plantarme, for use in our flavors and fragrances.”

Nerolidol is first in a full range of natural ingredients in the 2022 pipeline of Blue California's Taste, Smell, and Beauty Division. Conagen develops one of the most high–yielding fermentation platforms for producing sesquiterpenes and lactones.

With its functional advantages in many industries due to its moderate polarity and optical activity, nerolidol is also a useful, sustainable fine chemical intermediate.

“Nerolidol is a foundational material with many uses in many markets. Plantarme S is a sandalwood type material, and Plantarme M, which is a natural musk, are both creating a lot of excitement in the marketplace,” said Oglesby.

Until now, synthetic musk was primarily used in the fragrance industry because traditional musk sources were wild plants, too rare to be useful, or wild animals, like musk deer and civet cats, too endangered to be ethical. Conagen and Blue California have teamed together to develop a modern, one–of–a–kind, natural, domestic plant–derived musk that is safe, versatile, and biodegradable.

“The launch of nerolidol is symbolic of the collaboration between Blue California and Conagen as we advance in the markets we can serve,” said Casey Lippmeier, Ph.D. vice president of innovation at Conagen. “Together, we are revolutionizing the flavor and fragrance ingredient industry with our disruptive capabilities for producing clean, sustainable solutions and product applications.”

About Blue California

Blue California is an entrepreneurial, science–based solutions provider and manufacturer of clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products. For more than 25 years, Blue California has built a strong reputation for creating value in these diverse natural products and nature–inspired industries. www.bluecal–ingredients.com

About Conagen

Conagen is a product–focused, synthetic biology R&D company with large–scale manufacturing affiliates. Our scientists and engineers use the latest synthetic biology tools to develop high–quality, sustainable, nature–based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high–value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachments


GLOBENEWSWIRE (Distribution ID 8412058)

Blue California Expands Natural Flavor and Fragrance Portfolio with Production of Clean, Natural, and Sustainable Nerolidol

Rancho Santa Margarita, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) — Blue California announced the expansion of its natural flavor and fragrance portfolio of captive ingredients by producing a clean, sustainable nerolidol.

Nerolidol is a rare sesquiterpene alcohol ubiquitous in nature and found in many flowers and plants, particularly in Seville orange flower, also known as Neroli, which gives the aroma chemical its name.

It is recognized for its floral, woody aroma and can also be described as a fresh scent, blending well with citrus, apple, or rose but light enough to complement any type of scent or flavor. Nerolidol is therefore ideal for use in many applications and known for its relaxing effects.

Many brands looking to make products at a large scale using nerolidol find it to be cost–prohibitive and, for that reason, it hasn't been widely used in modern–day product applications.

Yet, consumers seek clean–label fragrance products that are easy on the planet and fit into the clean and conscious fragrance and beauty movement. The Innova Beauty & Personal Care Survey 2020 notes that 51% of global consumers indicate that natural ingredients are very or extremely important to them when purchasing fragrances.

“Biotechnology is opening doors to sustainable ingredients that weren't previously possible,” said Kathy Oglesby, head of flavors and fragrances at Blue California. “Our collaboration with innovation partner Conagen provides efficient and effective commercialization, leading us to deliver to our client–creators a full range of captive ingredients, trademarked Plantarme, for use in our flavors and fragrances.”

Nerolidol is first in a full range of natural ingredients in the 2022 pipeline of Blue California's Taste, Smell, and Beauty Division. Conagen develops one of the most high–yielding fermentation platforms for producing sesquiterpenes and lactones.

With its functional advantages in many industries due to its moderate polarity and optical activity, nerolidol is also a useful, sustainable fine chemical intermediate.

“Nerolidol is a foundational material with many uses in many markets. Plantarme S is a sandalwood type material, and Plantarme M, which is a natural musk, are both creating a lot of excitement in the marketplace,” said Oglesby.

Until now, synthetic musk was primarily used in the fragrance industry because traditional musk sources were wild plants, too rare to be useful, or wild animals, like musk deer and civet cats, too endangered to be ethical. Conagen and Blue California have teamed together to develop a modern, one–of–a–kind, natural, domestic plant–derived musk that is safe, versatile, and biodegradable.

“The launch of nerolidol is symbolic of the collaboration between Blue California and Conagen as we advance in the markets we can serve,” said Casey Lippmeier, Ph.D. vice president of innovation at Conagen. “Together, we are revolutionizing the flavor and fragrance ingredient industry with our disruptive capabilities for producing clean, sustainable solutions and product applications.”

About Blue California

Blue California is an entrepreneurial, science–based solutions provider and manufacturer of clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products. For more than 25 years, Blue California has built a strong reputation for creating value in these diverse natural products and nature–inspired industries. www.bluecal–ingredients.com

About Conagen

Conagen is a product–focused, synthetic biology R&D company with large–scale manufacturing affiliates. Our scientists and engineers use the latest synthetic biology tools to develop high–quality, sustainable, nature–based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high–value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachments


GLOBENEWSWIRE (Distribution ID 8412058)

Nikkiso Clean Energy & Industrial Gases Group Becomes Ambassador Member of California Fuel Cell Partnership

TEMECULA, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to announce they have joined the California Fuel Cell Partnership (CaFCP) as an Ambassador.

The association is driving to establish 200 hydrogen fueling stations by 2025 for a sustainable future for zero emission cars, trucks and buses. Joining the CaFCP is part of the Group's commitment to leading the change to a healthier world. Furthermore, the Group is expanding their global operations, opening a new engineering and service facility in Houston and Korea this year, and a new center in Germany in 2022.

"We are excited to be part of CaFCP to provide clean energy alternatives and look forward to collaborate with other CaFCP members in the fuel cell hydrogen fuel market," according to Peter Wagner, CEO, Nikkiso Clean Energy & Industrial Gases Group.

There are several new hydrogen products under development, such as the first mobile Hydrogen refueler pumps, high capacity / high pressure reciprocating hydrogen pumps and containerized liquid hydrogen re–fueling stations. This is in addition to their ability to provide engineering, procurement, and full turnkey projects.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small–scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com


GLOBENEWSWIRE (Distribution ID 8411843)

Mullen and ARRK, a Leading German Automotive Engineering Company, Announce Partnership for Upcoming Mullen FIVE EV Crossover

The companies will be working together on Mullen's entire EV lineup, starting with the Mullen FIVE EV Crossover. ARRK, with over 3,500 employees globally, will assign up to 180 engineers in supporting Mullen's EV development, ensuring the highest performance targets and regulatory compliance for passive safety, active safety, and noise, vibration and harshness ("NVH').

BREA, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) ("Mullen" or the "Company"), an emerging electric vehicle ("EV") manufacturer, announces today a strategic partnership with ARRK, a leading automotive engineering company based in Munich, Germany.

ARRK will be supporting Mullen Automotive in Computer Aided Engineering (CAE), body in white, battery, closures, interior, chassis, thermal, and infotainment engineering. ARRK initial support will be for the Mullen FIVE EV Crossover and then move into future vehicles, including a seven–seat SUV program.

“ARRK is a leading automotive engineering company with a global footprint, including working with some of the most well–respected automotive manufacturers, such as BMW, VW brands and Mercedes–Benz. Their vehicle engineering expertise will be a key component for us in hitting our production timeline for the FIVE and beyond," said David Michery, CEO and chairman of Mullen Automotive.

"Supporting the engineering development of the Mullen FIVE vehicle for global CAE, body development with closures, high voltage battery housing, interior, chassis, thermal management and infotainment for the next 3–year period will be a great challenge for us at ARRK," said Florian Gerber, vice president of development for body, high voltage battery, interior and exterior, and composite at ARRK. "We are very pleased about this cooperation and are looking forward to shaping the electric car future together with Mullen."

About Mullen

Mullen is a Southern California–based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the Company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer's life. Mullen strives to make EVs more accessible than ever by building an end–to–end ecosystem that takes care of all aspects of EV ownership.

About ARRK

ARRK is a globally active development partner for the automotive and mobility industry, specializing in end–to–end and comprehensive support of the entire product development process – from the concept phase through series development to validation and system integration of mechanical and electronic components.

Being a partner with a strong customer focus, ARRK can offer all its services to make a product ready for series production – from styling, engineering, prototyping, tooling to low volume production.

Contact:

ARRK Engineering GmbH

info@arrk–engineering.com
www.arrk–engineering.com

Forward–Looking Statements

This press release contains “forward–looking statements.” Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, often signify forward–looking statements. These forward–looking statements include, without limitation, statements relating to the reverse merger, the Nasdaq approval process and proposed debut date of the Mullen FIVE (formerly MX–05) midsize crossover. These forward–looking statements are, by their nature, subject to significant risks and uncertainties.

Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward–looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward–looking statements, including factors beyond the Company's control. As a result of these and other risks, uncertainties and assumptions, forward–looking events and circumstances discussed herein might not occur in the way the Company expects or at all. Accordingly, readers should not place reliance on any forward–looking information or statements. The Company assumes no obligation to publicly update or revise its forward–looking statements as a result of new information, future events or otherwise. All forward–looking statements herein are qualified by reference to the cautionary statements set forth in this section.

Contact:

Mullen Automotive, Inc.
+1 (714) 613–1900
www.MullenUSA.com

Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217
Editor@InvestorWire.com


GLOBENEWSWIRE (Distribution ID 8411583)

Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant

WALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases with pandemic potential, today provided an update following external in vitro analyses to evaluate neutralizing activity of ADG20 against the Omicron SARS–CoV–2 variant. The in vitro data generated through both authentic and pseudovirus testing of the Omicron variant show a greater than 300–fold reduction in neutralizing activity of ADG20 against Omicron. Additional analyses are ongoing, and the company plans to engage with regulatory and government agencies to assess the role ADG20 can play for the prevention and treatment of COVID–19, particularly as the industry's understanding of the epidemiology and impact of Omicron and potential new variants develops.

"Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we anticipated that ADG20 would retain neutralizing activity against Omicron, consistent with activity observed in in vitro models with all other known variants of concern," said Tillman Gerngross, Ph.D., chief executive officer of Adagio. "While the individual mutations present in the Omicron receptor binding domain were not associated with escape from ADG20 in the context of an original strain of the virus, new data show that the combination of mutations present in the Omicron spike protein led to a reduction in ADG20 neutralization that was not suggested by prior data. The continued prevalence of the Delta variant in the U.S. and other countries, evolution of SARS–CoV–2 variants and potential future coronaviruses means a multitude of therapies and approaches are needed. With an expert team committed to advancing antibody solutions that combat this unprecedented pandemic and a strong balance sheet, we're conducting additional analyses to assess the optimal path forward with ADG20 as both a prophylactic and treatment option for COVID–19."

ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS–CoV–2, including variants of concern, for the prevention and treatment of COVID–19 with potential duration of protection for up to one year with a single injection. In previously disclosed in vitro studies, ADG20 retained activity against prior variants of concern including Alpha, Beta, Delta and Gamma. In addition, in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS–CoV–2 variants, including the Lambda, Mu and Delta plus variants. The safety and efficacy of ADG20 have not been established, and ADG20 is not authorized or approved for use in any country.

Adagio is currently evaluating ADG20 in global Phase 2/3 clinical trials for both the prevention and treatment of COVID–19. Based on the in vitro findings related to Omicron, Adagio plans to pause patient recruitment in its Phase 2/3 COVID–19 treatment trial at clinical sites in South Africa, where Omicron has emerged as the dominant variant. Adagio is evaluating next steps for its ADG20 program.

In vitro analyses were also conducted on ADG10, a second mAb in development, which showed minimal neutralizing activity against the Omicron variant in both authentic and pseudovirus neutralization assays.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases with pandemic potential, including COVID–19 and influenza. The company's portfolio of antibodies has been optimized using Adimab's industry–leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half–life extension), manufacturability and affordability. Adagio's portfolio of SARS–CoV–2 antibodies includes multiple non–competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third–party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward–looking statements. Forward–looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of future program updates and the initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the additional and ongoing analyses to evaluate the activity of ADG20 against the Omicron variant and the potential of ADG20 to play a role as both a prophylactic and a treatment option for COVID–19; the risk/benefit profile of our product candidates to patients; and the adequacy of our cash, cash equivalents and marketable securities. We may not actually achieve the plans, intentions or expectations disclosed in our forward–looking statements and you should not place undue reliance on our forward–looking statements. These forward–looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward–looking statements, including, without limitation, the impacts of the COVID–19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward–looking statements in this press release are described under the heading "Risk Factors" in Adagio's Quarterly Report on Form 10–Q for the quarter ended September 30, 2021 and in Adagio's future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID–19 pandemic. Forward–looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact: Investor Contact:
Dan Budwick, 1AB Monique Allaire, THRUST Strategic Communications
Dan@1abmedia.com monique@thrustsc.com


GLOBENEWSWIRE (Distribution ID 8411191)

LeddarTech to Showcase Critical Sensing and Perception Solutions Enabling ADAS and Autonomous Driving at CES Las Vegas 2022

QUEBEC, Dec. 14, 2021 (GLOBE NEWSWIRE) — LeddarTech , a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, is pleased to announce its participation at five CES Las Vegas locations, January 5–8 '22. The LeddarTech Showcase location will demonstrate four new leading solutions that enable OEMs, Tier 1–2 suppliers, system integrators and LiDAR manufacturers to solve critical ADAS and AD sensing and perception challenges across the entire value chain of the automotive, mobility and off–road vehicle markets. In addition, LeddarTech will also be present at four other Ecosystem Partner locations.

Introducing the LeddarTech Showcase (Booth #7061, LVCC West Hall)

The theme of LeddarTech's CES destination booth (#7061) is "Solving Critical Sensing and Perception Challenges in ADAS and AD." The booth, located in the all–new LVCC West Hall, in the heart of the Transportation/Vehicle Technology section, will feature groundbreaking technologies and solutions.

LeddarTech welcomes CES delegates to see firsthand solutions that address critical issues facing customers:

  1. Uncover the benefits of raw data fusion with LeddarVision
    A comprehensive open sensor fusion and perception solution for automotive and off–road industrial vehicle ADAS and autonomous L2–L5 driving applications.
  2. Maximize LiDAR performance with LeddarSteer DBSD
    A scalable, adaptable and reliable solid–state, automotive–grade digital beam steering device (DBSD) for LiDAR manufacturers and vision system developers enhances range and resolution while optimizing costs and form factors.
  3. Explore a LiDAR development solution that reduces risk, costs and time, enabling faster time–to–market with the LiDAR XLRator
    A versatile LiDAR development platform and auto–grade reference design solution. The XLRator is powered by the LeddarEngine (SoC and signal processing software) and critical components from development collaborators, ams OSRAM, STMicroelectronics and TE First Sensor that enable LiDAR manufacturers and Tier 1–2s and system integrators to develop automotive–grade LiDAR sensors meeting the specific requirements of OEMs. The XLRator platform also integrates the LeddarSteer DBSD.
  4. View the benefits of the LeddarEcho simulation tool in reducing development time
    A SiL sensor simulation software application for ADAS/AD system developers and integrators that models various sensor architectures and components to develop optimal LiDAR designs and validate the resulting performance within specific application use cases.

Also, visit LeddarTech at their Ecosystem Partner locations:

dSPACE (Booth #3555, LVCC West Hall), a company whose solutions have accelerated the development of innovative vehicle technology for decades, will host LeddarTech in demonstrating the LeddarEcho high–precision simulation tools and models created to support and significantly accelerate the development and validation of LeddarEngine–based LiDAR sensors and related ADAS & AD systems.

The Canadian Automotive Parts and Manufacturers' Association (APMA) (Booth #6367, LVCC West Hall) is Canada's national association representing OEM producers of parts, equipment, tools, supplies and advanced technology services for the worldwide automotive industry. LeddarTech is a proud member of the association and a technical contributor in the autonomous vehicle initiative "Project Arrow."

Gouvernement du Qubec – Investissement Qubec (Booth #51827, The Venetian Expo, 2nd floor, 201 Sands Avenue, Las Vegas) is the go–to partner for international businesses thinking of locating to Qubec. They also support the efforts made by Qubec companies to access and expand into innovative markets. LeddarTech is proud to be a delegate on its CES trade mission. The company will be highlighting its sensor solutions for ITS and mobility applications.

Set a meeting with LeddarTech at CES:

LeddarTech will have representatives from all divisions available. You are invited to pre–arrange a meeting HERE for product demonstrations, media interviews, industry analyst or investor discussions, enquire about joining the Leddar Ecosystem or learn about the incredible career opportunities available. The team will be there to greet you at the booth or meet with you ""by appointment only"" in the LeddarTech business lounge #W318 at LVCC West Hall "" Level 3.

About LeddarTech

LeddarTech provides the most flexible, robust and accurate sensing technology for advanced driver assistance systems (ADAS) and autonomous driving (AD). LeddarTech enables customers to solve critical environmental sensing, fusion and perception challenges across the entire value chain. The company offers cost–effective, scalable solutions such as LeddarVision, a raw–data sensor fusion and perception platform that generates a comprehensive 3D environmental model with multi–sensor support for camera, radar and LiDAR configurations. LeddarTech supports LiDAR makers and Tier 1–2 automotive system integrators with LeddarSteer, a digital beam steering device, and the LiDAR XLRator development solution for automotive–grade solid–state LiDAR based on the LeddarEngine and core components from global semiconductor partners. LeddarTech is responsible for several cutting–edge remote–sensing innovations, with over 100 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice–President, Global Marketing, Communications and Product Management, LeddarTech Inc.
Tel.: + 1–418–653–9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.


GLOBENEWSWIRE (Distribution ID 8410935)

Mullen To Showcase The FIVE EV Crossover and Level 5 Autonomous Vehicle Technology at CES® (Consumer Electronic Show)

BREA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) ("Mullen" or the "Company"), an emerging electric vehicle ("EV") manufacturer, announces that its next stop in showcasing the Mullen FIVE EV Crossover, including the debut of level 5 autonomous vehicle technology, will be at CES in Las Vegas, Jan. 4 "" 8, 2022. Mullen will showcase the FIVE and vehicle technology with media presentation Wednesday, Jan. 5, 2022, at the Mullen Booth, located in the West Hall of the LA Convention Center.

"Our next stop is CES in Las Vegas this coming January. We had tremendous, overwhelmingly positive reaction to the FIVE at the L.A. Auto Show, with many people saying it was the best–looking vehicle at the show and winning the Top SUV EV category, beating out both Rivian and Lincoln," said David Michery, CEO and chairman of Mullen Automotive. "CES is a one of the best, if not the best, consumer technology event in the world. We are looking forward to starting 2022 in Las Vegas at CES with the Mullen FIVE EV Crossover."

Mullen Automotive and the FIVE EV Crossover will be at the Consumer Electronics Show (CES ) in Las Vegas, Jan. 5 – 8, 2022. Mullen will be featured in the West Hall of the Las Vegas Convention Center for the duration of the CES , showcasing the FIVE, including autonomous, powertrain and battery technology.

The FIVE is built on an EV crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is "Strikingly DifferentTM" and exciting to experience in person. Learn more about the Mullen FIVE at MullenUSA.com.

About Mullen

Mullen is a Southern California–based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the Company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer's life. Mullen strives to make EVs more accessible than ever by building an end–to–end ecosystem that takes care of all aspects of EV ownership.

Forward–Looking Statements
This press release contains “forward–looking statements.” Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, often signify forward–looking statements. These forward–looking statements include, without limitation, statements relating to the reverse merger, the Nasdaq approval process and proposed debut date of the Mullen FIVE (formerly MX–05) midsize crossover. These forward–looking statements are subject to risks and uncertainties.

Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward–looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward–looking statements, including factors beyond the Company's control. As a result of these and other risks, uncertainties and assumptions, forward–looking events and circumstances discussed herein might not occur in the way the Company expects or at all. Accordingly, readers should not place reliance on any forward–looking information or statements. The Company assumes no obligation to publicly update or revise its forward–looking statements as a result of new information, future events or otherwise. All forward–looking statements herein are qualified by reference to the cautionary statements set forth in this section.

Contact:

Mullen Automotive, Inc.
+1 (714) 613–1900
www.MullenUSA.com

Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217
Editor@InvestorWire.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e9297637–6743–449a–afdd–c230a337dfa4


GLOBENEWSWIRE (Distribution ID 8410332)